Exelixis, Inc. Hits New 52-Week High of $52.96, Soars 132.49%

Exelixis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 52.96 on May 28, 2026. This achievement underscores the company's robust performance, with a remarkable one-year return of 132.49%, significantly outpacing the S&P 500's 28.45% return during the same period. The company's financial metrics reflect strong underlying fundamentals. Exelixis boasts a price-to-earnings (P/E) ratio of 13.00, indicating an attractive valuation relative to its earnings. Additionally, the firm has demonstrated impressive growth, with net sales increasing at an annual rate of 18.63% and a net profit growth of 31.86% reported in its latest results. The return on equity (ROE) stands at an impressive 36.94%, further highlighting the company's efficiency in generating profits from its equity. Exelixis maintains a net-debt-free status, with a debt-to-equity ratio of -0.48, and has consistently delivered positive results over the last three quarters. With high institutional holdings at 100%, the company is well-positioned within its industry, reflecting confidence from sophisticated investors.